Critical signal transduction pathways in CLL

Asish K. Ghosh, Neil E. Kay

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages215-239
Number of pages25
Volume792
DOIs
StatePublished - 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume792
ISSN (Print)00652598

Fingerprint

Signal transduction
B-Cell Chronic Lymphocytic Leukemia
Signal Transduction
Cells
Receptor Protein-Tyrosine Kinases
B-Lymphocytes
Protein-Tyrosine Kinases
Phosphotransferases
Chemical activation
Cytokines
src-Family Kinases
Cell Surface Receptors
Cell- and Tissue-Based Therapy
Cell Survival
Intercellular Signaling Peptides and Proteins
Apoptosis
Plasmas
Therapeutics

Keywords

  • Apoptosis
  • CLL
  • Kinase inhibitor
  • Non-RTK
  • RTK
  • Signal transduction
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ghosh, A. K., & Kay, N. E. (2013). Critical signal transduction pathways in CLL. In Advances in Experimental Medicine and Biology (Vol. 792, pp. 215-239). (Advances in Experimental Medicine and Biology; Vol. 792). https://doi.org/10.1007/978-1-4614-8051-8-10

Critical signal transduction pathways in CLL. / Ghosh, Asish K.; Kay, Neil E.

Advances in Experimental Medicine and Biology. Vol. 792 2013. p. 215-239 (Advances in Experimental Medicine and Biology; Vol. 792).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ghosh, AK & Kay, NE 2013, Critical signal transduction pathways in CLL. in Advances in Experimental Medicine and Biology. vol. 792, Advances in Experimental Medicine and Biology, vol. 792, pp. 215-239. https://doi.org/10.1007/978-1-4614-8051-8-10
Ghosh AK, Kay NE. Critical signal transduction pathways in CLL. In Advances in Experimental Medicine and Biology. Vol. 792. 2013. p. 215-239. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-8051-8-10
Ghosh, Asish K. ; Kay, Neil E. / Critical signal transduction pathways in CLL. Advances in Experimental Medicine and Biology. Vol. 792 2013. pp. 215-239 (Advances in Experimental Medicine and Biology).
@inbook{4bf77711d4d64385a5c00230d6e1cfeb,
title = "Critical signal transduction pathways in CLL",
abstract = "Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.",
keywords = "Apoptosis, CLL, Kinase inhibitor, Non-RTK, RTK, Signal transduction, Therapy",
author = "Ghosh, {Asish K.} and Kay, {Neil E.}",
year = "2013",
doi = "10.1007/978-1-4614-8051-8-10",
language = "English (US)",
isbn = "9781461480501",
volume = "792",
series = "Advances in Experimental Medicine and Biology",
pages = "215--239",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Critical signal transduction pathways in CLL

AU - Ghosh, Asish K.

AU - Kay, Neil E.

PY - 2013

Y1 - 2013

N2 - Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

AB - Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

KW - Apoptosis

KW - CLL

KW - Kinase inhibitor

KW - Non-RTK

KW - RTK

KW - Signal transduction

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84884995732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884995732&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8051-8-10

DO - 10.1007/978-1-4614-8051-8-10

M3 - Chapter

SN - 9781461480501

VL - 792

T3 - Advances in Experimental Medicine and Biology

SP - 215

EP - 239

BT - Advances in Experimental Medicine and Biology

ER -